Litigation Details for TAKEDA PHARMACEUTICAL COMPANY LTD. v. TORRENT PHARMACEUTICALS LTD. (D.N.J. 2017)

TAKEDA PHARMACEUTICAL COMPANY LTD. v. TORRENT PHARMACEUTICALS LTD. (D.N.J. 2017)

Docket		Date Filed	2017-05-05
Court	District Court, D. New Jersey	Date Terminated
Cause	35:145 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To
Patents	7,807,689
Link to Docket	External link to docket

Details for TAKEDA PHARMACEUTICAL COMPANY LTD. v. TORRENT PHARMACEUTICALS LTD. (D.N.J. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-02-04	126	Opinion	double patenting. 17. Claims 4 and 12 of U.S. Patent No. 7,807,689 are valid patent claims.…Torrent.”) Plaintiffs own U.S. Patent No. 7,807,689 (“the ’689 patent”), which is listed in the Orange…second patent for claims that are not patentably distinct from the claims of the first patent. It …claims in a second patent not patentably distinct from the claims of the first patent. The obviousness-type… claims 4 and 12 of the ’689 patent. A bench trial on Defendants’ patent invalidity defenses to infringement	External link to document
2021-02-15	136	Opinion - USCA	challenges to claims 4 and 12 of U.S. Patent No. 7,807,689, owned by Takeda. 1 See Takeda Pharm… or non-statutory obviousness-type double patenting. In their appeal, Appellants challenge… Torrent presents two obviousness-type double patent- ing theories using Feng’s 2 F162 …not 2 Feng refers to U.S. Patent No. 7,723,344. 3 Böhm refers…J.A. 33496–715 (“Mark 2004,” another patent reference pertaining to xan- thine-based	External link to document